Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 922 participants.
Also called NCT01031680
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 922 participants
- Sponsor
- Registry
-
NCT01031680
-
- Other papers using this trial's data
- Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Canada, Germany, Romania, Slovakia, Spain, Taiwan, Vietnam
- Registry status
- Completed
Technical summary
Registry record NCT01031680. Randomized; quadruple masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2011-05 (actual). Results posted on 2013-08-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Cardiovascular Disease
- Condition
- Hypertension
- Condition
- Inadequate Glycaemic Control
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
- Collaborator
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct01031680- Content hash
52dbda51c6cff4dbe0eddbc41986b2952e369c55212d5c7f22a6bc3713f2046e